CCL3 Signaling in the Tumor Microenvironment

  • Adv Exp Med Biol. 2020;1231:13-21. doi: 10.1007/978-3-030-36667-4_2.
Ioannis Ntanasis-Stathopoulos  1 ,  Despoina Fotiou  1 ,  Evangelos Terpos  2
Affiliations
  • 1. Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
  • 2. Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece. [email protected].
PMID: 32060842 DOI: 10.1007/978-3-030-36667-4_2
Abstract

Within the tumor microenvironment, chemokines play a key role in immune cell trafficking regulation and immune landscape formulation. CCL3 or macrophage inflammatory protein-1α (MIP-1α), an important chemokine implicated in both immune surveillance and tolerance, has emerged as a prognostic biomarker in both solid and hematological malignancies. CCL3 exerts both antitumor and pro-tumor behavior which is context dependent highlighting the complexity of the underlying interrelated signaling cascades. Current CCL3-directed therapeutic approaches are investigational and further optimization is required to increase efficacy and minimize adverse events.

Keywords
CCL2; CCL3; CCR1; CCR4; CCR5; Chemokine; Chemokines; Immune cell; Lymph node; MIP-1a; Macrophage inflammatory protein-1 alpha; Metastasis-associated macrophages; T cell; Tumor microenvironment; Tumor-associated macrophages.
Products